Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Incyte is a biopharmaceutical company focused on oncology and inflammation, with its core commercial franchise built around Jakafi (ruxolitinib) for myelofibrosis and polycythemia vera, generating approximately 60% of revenue. The company has expanded into solid tumor oncology with Pemazyre, Monjuvi, and Iclusig, while maintaining a robust pipeline including pivotal-stage assets in dermatology (ruxolitinib cream) and hematology. Stock performance is driven by Jakafi lifecycle management, new product launches, and clinical trial readouts for pipeline assets targeting multi-billion dollar addressable markets.
Incyte operates a specialty pharmaceutical model with high-margin branded drugs in niche oncology and rare disease markets. Jakafi commands premium pricing ($150K+ annual cost) due to lack of direct competition in myelofibrosis, with pricing power sustained through label expansions and lifecycle management. The 91.5% gross margin reflects minimal COGS for small-molecule manufacturing. Operating leverage comes from fixed R&D infrastructure supporting multiple pipeline programs, while commercial infrastructure scales efficiently across the oncology portfolio. Partnership royalties from Olumiant provide high-margin, capital-light revenue. The company reinvests approximately 35-40% of revenue into R&D to maintain pipeline velocity.
Jakafi revenue trajectory and competitive threats from emerging JAK inhibitors (pacritinib, fedratinib)
Clinical trial readouts for ruxolitinib cream in atopic dermatitis and vitiligo (multi-billion dollar addressable markets)
New product launch performance - Pemazyre uptake in cholangiocarcinoma, Monjuvi in lymphoma
Pipeline development milestones - Phase 3 data for INCB054329 (BET inhibitor), tafasitamab combinations
Business development activity - licensing deals, acquisitions to supplement organic pipeline
Generic/biosimilar threats to Jakafi (patent cliff timing around 2028-2030)
Jakafi patent cliff (2028-2030) represents 60% revenue exposure to generic/biosimilar competition, requiring successful pipeline execution to offset
Pricing pressure from Medicare negotiation provisions in Inflation Reduction Act - Jakafi likely subject to negotiation given revenue scale and time on market
Regulatory risk for accelerated approvals - Pemazyre and other assets approved on single-arm trials face confirmatory study requirements with withdrawal risk
JAK inhibitor competition intensifying - pacritinib (CTI BioPharma) approved for myelofibrosis with differentiated cytopenia profile, fedratinib (BMS) gaining share
Ruxolitinib cream faces competition from Pfizer's JAK inhibitors (Cibinqo oral, potential topical formulations) in dermatology
Oncology portfolio operates in crowded markets - FGFR inhibitors (Pemazyre) face competition from Janssen, Taiho; BTK inhibitors emerging in lymphoma
Minimal financial risk - negligible debt, strong cash generation, but $1.4B annual FCF may attract activist pressure for capital return vs. R&D investment
Acquisition integration risk if pursuing large M&A to offset Jakafi cliff - company historically focused on internal development
low - Oncology and rare disease treatments are non-discretionary with inelastic demand. Patients continue therapy regardless of economic conditions. However, severe recessions can impact diagnosis rates (fewer doctor visits) and insurance coverage generosity. The 21.2% revenue growth during recent economic uncertainty demonstrates resilience.
Rising rates create modest headwinds through two mechanisms: (1) Higher discount rates compress valuation multiples for growth-stage biopharma, particularly impacting pipeline NPV calculations that investors use for sum-of-the-parts models. (2) The $3.3B cash position generates higher interest income in rising rate environments (modest positive), but this is overwhelmed by multiple compression. The 0.01 debt/equity ratio means financing costs are negligible. Primary impact is valuation-driven rather than operational.
minimal - Biopharma operates on cash basis with minimal receivables risk. Payer mix is predominantly commercial insurance and Medicare Part D with low bad debt exposure. The 3.32 current ratio and $1.4B free cash flow generation eliminate refinancing risk. Credit conditions affect M&A financing availability but not core operations.
growth - The 21.2% revenue growth, expanding operating margins (26.1%), and 4,018% EPS growth attract growth investors focused on earnings inflection. The 44.4% one-year return reflects momentum following profitability inflection. Minimal dividend (not mentioned in fundamentals) and high R&D reinvestment rate signal growth prioritization over income. The $20B market cap positions INCY as a mid-cap growth name with acquisition potential, attracting both fundamental long-only growth funds and event-driven strategies.
high - Biotech stocks exhibit elevated volatility driven by binary clinical trial events, FDA decisions, and competitive developments. The -4.1% three-month return vs. +17.8% six-month return demonstrates headline-driven swings. Typical biotech beta of 1.2-1.5x market. Volatility spikes around key data readouts (ruxolitinib cream results) and competitive threats (new JAK inhibitor approvals).
